Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan |
| |
| Authors: | Yutaka Tokuda Yasuhiro Suzuki Masatoshi Ohta Yuki Saito Mitsuhiro Kubota Tomoo Tajima Shinobu Umemura R. Yoshiyuki Osamura |
| |
| Affiliation: | Department of Surgery, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan. tokuda@is.icc.u-tokai.ac.jp |
| |
| Abstract: | The HER-2/neu protein is thought to be a unique and useful target for antibody therapy of cancers overexpressing the HER-2/neu gene. The recombinant humanized anti-HER-2 monoclonal antibody, trastuzumab (Herceptin) was approved for clinical use in the US in 1998. In Japan, it was approved and later became available in June, 2001. We have treated 41 patients with metastatic breast cancer with trastuzumab purchased from the US. In this paper, the details of the patients we experienced are reviewed. |
| |
| Keywords: | HER2/neu Humanized monoclonal antibody Trastuzumab Breast cancer |
| 本文献已被 SpringerLink 等数据库收录！ |
|
